Literature DB >> 7833249

Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests.

A Osterborg1, Q Yi, S Bergenbrant, G Holm, A K Lefvert, H Mellstedt.   

Abstract

Idiotype-specific T cells were characterized in patients with multiple myeloma stage I by analysing idiotype-induced DNA synthesis (3H-thymidine incorporation), IL-2 and IFN-gamma production at the single cell level (ELISPOT) (in vitro tests) and delayed type hypersensitivity (DTH) skin reaction (in vivo test). In seven out of eight patients at least one of the four tests was positive. In five patients three or more tests were positive. One patient was negative in all four tests. Six patients had both IL-2 and IFN-gamma-secreting cells and three of them also a DTH response. Furthermore, those three patients with a proliferative response also had IL-2 and IFN-gamma-secreting cells induced by the idiotype. The data indicate that part of the idiotype-specific T cell fraction belongs to the CD4 Th1 cell population. Whether CD8-specific T cells also were present could not be ruled out. The present study provides further support for the existence of idiotype-specific T cells in multiple myeloma. Such cells might be an important target for an immune-mediated therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7833249     DOI: 10.1111/j.1365-2141.1995.tb08902.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  T cell receptor usage in autoimmune disease.

Authors:  P Moss; J Bell
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

Review 3.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

4.  Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

Authors:  Sivasubramanian Baskar; Carol B Kobrin; Larry W Kwak
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

5.  Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Authors:  Sungyoul Hong; Jianfei Qian; Jing Yang; Haiyan Li; Larry W Kwak; Qing Yi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

6.  Multiple myeloma: VI International Workshop, June 14-18, 1997, Boston, Massachusetts, USA.

Authors:  S Bergenbrant
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

7.  Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

Authors:  Katy J McCann; Rosemary Godeseth; Lindsey Chudley; Ann Mander; Gianfranco Di Genova; Paul Lloyd-Evans; Jonathan P Kerr; Vladimir B Malykh; Matthew W Jenner; Kim H Orchard; Freda K Stevenson; Christian H Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2015-05-16       Impact factor: 6.968

8.  One-pot, mix-and-read peptide-MHC tetramers.

Authors:  Christian Leisner; Nina Loeth; Kasper Lamberth; Sune Justesen; Christina Sylvester-Hvid; Esben G Schmidt; Mogens Claesson; Soren Buus; Anette Stryhn
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.